相似文献
1
Stem cells in the trabecular meshwork: present and future promises.
Exp Eye Res. 2009 Apr;88(4):747-51. doi: 10.1016/j.exer.2008.10.024. Epub 2008 Nov 18.
2
Clinical, structural and molecular phototherapy effects of laser irradiation on the trabecular meshwork of human glaucomatous eyes.
Graefes Arch Clin Exp Ophthalmol. 1990;228(1):90-100. doi: 10.1007/BF02764299.
3
[Targetted ablation of the trabecular meshwork with excimer laser in primary open-angle glaucoma].
Ophthalmologe. 1996 Oct;93(5):565-8. doi: 10.1007/s003470050040.
4
Comparisons of Schlemm's canal and trabecular meshwork morphologies between juvenile and primary open angle glaucoma.
Exp Eye Res. 2021 Sep;210:108711. doi: 10.1016/j.exer.2021.108711. Epub 2021 Aug 2.
5
Morphological effects of argon laser trabeculoplasty upon the glaucomatous human meshwork.
Eye (Lond). 1989;3 ( Pt 6):719-26. doi: 10.1038/eye.1989.111.
6
Comparison of laser trabeculostimulation with laser trabeculoplasty in open-angle glaucoma.
Ann Ophthalmol. 1992 Jul;24(7):245-9.
7
Individual factors influencing trabecular morphology in glaucoma patients undergoing filtration surgery.
J Glaucoma. 2002 Jun;11(3):197-202. doi: 10.1097/00061198-200206000-00006.
8
iPSCs-Based Therapy for Trabecular Meshwork.
Handb Exp Pharmacol. 2023;281:277-300. doi: 10.1007/164_2023_671.
9
Loss of trabecular meshwork stem cells is correlated with open angle glaucoma.
Exp Eye Res. 2025 Apr;253:110296. doi: 10.1016/j.exer.2025.110296. Epub 2025 Feb 14.
10
One-year follow-up of laser trabeculoplasty using Q-switched frequency-doubled Nd:YAG laser of 523 nm wavelength.
Ophthalmic Surg Lasers. 2000 Sep-Oct;31(5):394-9.
引用本文的文献
1
Transcriptomic Differences Between Human Trabecular Meshwork Stem Cells and Trabecular Meshwork Cells Reveal Specific Biomarker Profiles.
Curr Issues Mol Biol. 2025 Jul 3;47(7):514. doi: 10.3390/cimb47070514.
2
Advances in Regenerative Medicine, Cell Therapy, and 3D Bioprinting for Glaucoma and Retinal Diseases.
Adv Exp Med Biol. 2025 Mar 26. doi: 10.1007/5584_2025_854.
3
Trabecular Meshwork Stem Cells for Glaucoma Treatment.
Methods Mol Biol. 2025;2858:143-158. doi: 10.1007/978-1-0716-4140-8_13.
4
Effects of Netarsudil-Family Rho Kinase Inhibitors on Human Trabecular Meshwork Cell Contractility and Actin Remodeling Using a Bioengineered ECM Hydrogel.
Front Ophthalmol (Lausanne). 2022 Jul 15;2:948397. doi: 10.3389/fopht.2022.948397. eCollection 2022.
5
Healing responses at the angle after micro-invasive glaucoma surgery-an AS-OCT study.
PLoS One. 2024 Jun 27;19(6):e0305740. doi: 10.1371/journal.pone.0305740. eCollection 2024.
6
Recreating the Trabecular Outflow Tissue on Implantable, Micropatterned, Ultrathin, Porous Polycaprolactone Scaffolds.
Bioengineering (Basel). 2023 Jun 2;10(6):679. doi: 10.3390/bioengineering10060679.
7
Simvastatin Attenuates Glucocorticoid-Induced Human Trabecular Meshwork Cell Dysfunction via YAP/TAZ Inactivation.
Curr Eye Res. 2023 Aug;48(8):736-749. doi: 10.1080/02713683.2023.2206067. Epub 2023 May 7.
8
A bibliometric analysis of the application of stem cells in glaucoma research from 1999 to 2022.
Front Cell Dev Biol. 2023 Jan 18;11:1081898. doi: 10.3389/fcell.2023.1081898. eCollection 2023.
9
Thrombospondin-1 Signaling Through the Calreticulin/LDL Receptor Related Protein 1 Axis: Functions and Possible Roles in Glaucoma.
Front Cell Dev Biol. 2022 May 27;10:898772. doi: 10.3389/fcell.2022.898772. eCollection 2022.
10
TGFβ2 Regulates Human Trabecular Meshwork Cell Contractility ERK and ROCK Pathways with Distinct Signaling Crosstalk Dependent on the Culture Substrate.
Curr Eye Res. 2022 Aug;47(8):1165-1178. doi: 10.1080/02713683.2022.2071943. Epub 2022 May 19.
本文引用的文献
1
Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2.
Nat Biotechnol. 2008 Nov;26(11):1269-75. doi: 10.1038/nbt.1502. Epub 2008 Oct 12.
2
Recent advances in cardiovascular regenerative medicine: the induced pluripotent stem cell era.
Expert Rev Cardiovasc Ther. 2008 Jul;6(6):803-10. doi: 10.1586/14779072.6.6.803.
3
Parthenogenesis as an approach to pluripotency: advantages and limitations involved.
Stem Cell Rev. 2008 Sep;4(3):127-35. doi: 10.1007/s12015-008-9027-z. Epub 2008 Jun 12.
4
Updates on stem cells and their applications in regenerative medicine.
J Tissue Eng Regen Med. 2008 Jun;2(4):169-83. doi: 10.1002/term.83.
5
[Regenerative medicine: history and perspectives].
Nihon Rinsho. 2008 May;66(5):825-30.
6
Stem cells: promises versus limitations.
Tissue Eng Part B Rev. 2008 Mar;14(1):53-60. doi: 10.1089/teb.2007.0216.
7
Strategies and new developments in the generation of patient-specific pluripotent stem cells.
Cell Stem Cell. 2007 Jun 7;1(1):39-49. doi: 10.1016/j.stem.2007.05.012.
8
Tissue engineering and regenerative science in pediatrics.
Pediatr Res. 2008 May;63(5):459-60. doi: 10.1203/PDR.0b013e3181739fbe.
9
Stem cell sources and therapeutic approaches for central nervous system and neural retinal disorders.
Neurosurg Focus. 2008;24(3-4):E11. doi: 10.3171/FOC/2008/24/3-4/E10.
10
Neuronal stem/progenitor cells in the vertebrate eye.
Dev Growth Differ. 2008 May;50(4):253-9. doi: 10.1111/j.1440-169X.2008.01006.x. Epub 2008 Mar 10.
Zotero 插件